🚀 go-pugleaf

Dernières parutions d'articles librement accessibles concernant le
récepteur d'oestrogènes dans le cancer du sein:
Most recent free articles on estrogen receptor and breast cancer:




Polymorphisms in genes involved in the estrogen pathway and
mammographic density.
Dumas I, Diorio C.
BMC Cancer. 2010 Nov 22;10(1):636.
http://www.biomedcentral.com/1471-2407/10/636


Prolylcarboxypeptidase regulates proliferation, autophagy, and
resistance to 4-hydroxytamoxifen-induced cytotoxicity in ER-positive
breast cancer cells.
Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z,
Levenson VV.
J Biol Chem. 2010 Nov 17.
http://www.jbc.org/content/early/2010/11/17/jbc.M110.143271.long


Aromatase inhibitor strategies in metastatic breast cancer.
McArthur HL, Morris PG.
Int J Women Health. 2010 Aug 9;1:67-72.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971713/?tool=pubmed


Breast cancer in Moroccan young women: a retrospective study.
Abahssain H, Ialya I, El Mrabet FZ, Ismaili N, Razine R, Tazi MA,
Mrabti H, El Mesbahi O, Benjaafar N, Abouqal R, Errihani H.
BMC Res Notes. 2010 Nov 8;3(1):286.
http://www.biomedcentral.com/1756-0500/3/286


A noncompetitive small molecule inhibitor of estrogen-regulated gene
expression and breast cancer cell growth that enhances proteasome-
dependent degradation of estrogen receptor {alpha}
Patterson NM, Cherian MT, Mao C, Aninye IO, Reynolds PD, Schiff R,
Hergenrother PJ, Nordeen SK, Wilson EM, Shapiro DJ.
J Biol Chem. 2010 Nov 1.
http://www.jbc.org/content/early/2010/11/01/jbc.M110.183723.long


Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated
expression of HBO1.
Wang WZ, Liu HO, Wu YH, Hong Y, Yang JW, Liu YH, Wu WB, Zhou L, Sun
LL, Xu JJ, Yun XJ, Gu JX.
J Exp Clin Cancer Res. 2010 Nov 1;29:140.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989947/?tool=pubmed


American society of clinical oncology/college of american pathologists
guideline recommendations for immunohistochemical testing of estrogen
and progesterone receptors in breast cancer.
Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S.
J Oncol Pract. 2010 Jul;6(4):195-7.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900870/?tool=pubmed


Is soy consumption good or bad for the breast?
Hilakivi-Clarke L, Andrade JE, Helferich W.
J Nutr. 2010 Dec;140(12):2326S-34S.
http://jn.nutrition.org/content/140/12/2326S.long


Statistical techniques to construct assays for identifying likely
responders to a treatment under evaluation from cell line genomic
data.
Huang EP, Fridlyand J, Lewin-Koh N, Yue P, Shi X, Dornan D, Burington
B.
BMC Cancer. 2010 Oct 27;10:586.
http://www.biomedcentral.com/1471-2407/10/586


Prologue to thematic minireview series: Nuclear Receptors in Biology
and Diseases.
Lingrel JB, Khan S.
J Biol Chem. 2010 Oct 19.
http://www.jbc.org/cgi/pmidlookup?view=long&pmid=20959445


Raloxifene inhibits tumor growth and lymph node metastasis in a
xenograft model of metastatic mammary cancer.
Shibata MA, Morimoto J, Shibata E, Kurose H, Akamatsu K, Li ZL,
Kusakabe M, Ohmichi M, Otsuki Y.
BMC Cancer. 2010 Oct 19;10:566.
http://www.biomedcentral.com/1471-2407/10/566


Assessment of clinical validity of a breast cancer risk model
combining genetic and clinical information.
Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds
DA.
J Natl Cancer Inst. 2010 Nov 3;102(21):1618-27.
http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=20956782


Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by
combined green tea polyphenol and histone deacetylase inhibitor in ERα-
negative breast cancer cells.
Li Y, Yuan YY, Meeran SM, Tollefsbol TO.
Mol Cancer. 2010 Oct 14;9:274.
http://www.molecular-cancer.com/content/9/1/274


Genome profiling of ERBB2-amplified breast cancers.
Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A,
Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben
Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M.
BMC Cancer. 2010 Oct 8;10:539.
http://www.biomedcentral.com/1471-2407/10/539


Maximum growth and survival of estrogen receptor-alpha positive breast
cancer cells requires the Sin3A transcriptional repressor.
Ellison-Zelski SJ, Alarid ET.
Mol Cancer. 2010 Sep 29;9:263.
http://www.molecular-cancer.com/content/9/1/263


Quantitative proteomics and transcriptomics addressing the estrogen
receptor subtype-mediated effects in T47D breast cancer cells exposed
to the phytoestrogen genistein.
Sotoca AM, Sollewijn Gelpke MD, Boeren S, Ström A, Gustafsson JA, Murk
AJ, Rietjens IM, Vervoort J.
Mol Cell Proteomics. 2010 Sep 30.
http://www.mcponline.org/content/early/2010/09/30/mcp.M110.002170.long


CYP2D6 testing to predict response to tamoxifen in women with breast
cancer. Pharmacogenomic.
Dahabreh I, Terasawa T, Castaldi P, Trikalinos
PLoS Curr. 2010 Sep 2;2. pii: RRN1176.
http://knol.google.com/k/issa-dahabreh/cyp2d6-testing-to-predict-response-to/3qgx0fg7r52v/1#















InTextoResearch, Baelen, Liège, Belgique (Belgium) & OncoWal/Wallogene
(Marc Lacroix, scimedweb@mail.com)